X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/09/2860084/0/en/Optimi-Health-Signs-Psilocybin-Supply-Agreement-With-New-Zealand-Based-M%C4%81tai-Medical-Research-Institute.html
https://www.globenewswire.com/news-release/2024/04/08/2859109/0/en/Psyence-Biomed-Partners-with-Fluence-and-iNGEN%C5%AB-CRO-to-Train-Research-Therapists-for-Phase-IIb-Psilocybin-Trial.html
https://www.globenewswire.com/news-release/2024/04/02/2855849/0/en/Optimi-Health-Receives-Finished-Product-Test-Results-and-Certificate-Of-Analysis-for-GMP-Natural-Psilocybin-Extract.html
https://www.globenewswire.com/news-release/2024/04/02/2855836/0/en/Revive-Therapeutics-Provides-Update-on-Psilocybin-Clinical-Study-for-Methamphetamine-Use-Disorder.html
https://www.globenewswire.com//news-release/2024/03/05/2840486/0/en/Rose-Hill-Leads-the-Way-in-Psilocybin-Production-with-Innovative-Geo-Thermal-Cultivation-Enhancements-in-Jamaica.html
https://www.nasdaq.com/press-release/incannex-announces-positive-topline-results-from-phase-2-psi-gad1-clinical-trial-of
https://www.fiercebiotech.com/cro/compass-pathways-hackensack-meridian-ink-research-deal-psilocybin-treatment
https://www.globenewswire.com//news-release/2023/12/19/2798886/0/en/Compass-Pathways-announces-investigational-COMP360-psilocybin-treatment-was-well-tolerated-in-phase-2-study-of-post-traumatic-stress-disorder.html
https://www.globenewswire.com/news-release/2023/12/06/2792081/0/en/Study-results-of-psilocybin-treatment-in-bipolar-II-depression-published-in-JAMA-Psychiatry.html
https://www.globenewswire.com//news-release/2023/11/15/2780782/0/en/Compass-Pathways-initiates-UK-component-of-global-phase-3-study-of-psilocybin-treatment-in-treatment-resistant-depression-and-launches-new-research-center.html
https://www.globenewswire.com//news-release/2023/11/06/2773942/0/en/Sunstone-Therapies-Announces-Start-of-First-Study-of-Multiple-Doses-of-Psilocybin-in-Treatment-of-Depression-in-Patients-with-Cancer.html
https://www.prnewswire.com/news-releases/canadian-veteran-dosed-with-first-cycle-of-apex-90-macrodose-psilocybin-in-apex-labs-early-access-program-301974977.html
https://www.globenewswire.com//news-release/2023/11/01/2771385/0/en/Reset-Pharma-Receives-Notice-of-Safe-to-Proceed-from-FDA-for-Investigational-New-Drug-IND-Application-for-Oral-Psilocybin-RSTP1000.html
https://phytonbiotech.com/phyton-controlled-substances-dealers-license-health-canada/
https://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-new-preclinical-data-on-its-psilocybin-program-at-aasld-the-liver-meeting-2023-301953616.html
https://www.globenewswire.com/news-release/2023/07/25/2710106/0/en/First-clinical-study-results-of-psilocybin-treatment-in-anorexia-nervosa-published-in-Nature-Medicine.html
https://www.globenewswire.com/news-release/2023/07/13/2704089/0/en/Opinion-paper-calls-for-clarity-on-the-definition-of-psychedelic-assisted-therapy-using-psilocybin.html
https://www.clinicaltrialsarena.com/news/tryp-fda-trial-psilocybin/
https://www.globenewswire.com/news-release/2023/05/18/2671936/0/en/Lucy-Scientific-Discovery-Inc-Accelerates-Psilocybin-Access-and-Product-Launch-through-a-Strategic-Partnership-with-TheraPsil.html
https://www.prnewswire.com/news-releases/apex-labs-granted-approval-for-160-patient-macrodose-multi-dose-psilocybin-clinical-trial-by-health-canada-301802969.html
https://www.newswire.ca/news-releases/filament-health-announces-fda-approval-of-phase-ii-clinical-trial-studying-psilocybin-for-methamphetamine-use-disorder-801405766.html
https://www.globenewswire.com/news-release/2023/03/06/2620922/0/en/Mindset-Pharma-and-PharmAla-Complete-First-Sale-of-Pharmaceutical-Grade-Psilocybin-Into-Growing-Australian-Market-via-Sales-Partnership.html
https://www.prnewswire.com/news-releases/apex-labs-granted-approval-for-294-patient-take-home-psilocybin-clinical-trial-301725784.html
https://www.accesswire.com/734097/Tryp-Therapeutics-Announces-Interim-Results-for-Its-Phase-II-Clinical-Trial-for-the-Treatment-of-Binge-Eating-Disorder-With-Psilocybin-Assisted-Psychotherapy
https://www.globenewswire.com/news-release/2022/12/15/2574620/0/en/Psyence-and-Filament-Health-Announce-Worldwide-Licensing-Agreement-of-Psilocybin-Capsule-for-Palliative-Care.html
https://www.prnewswire.com/news-releases/diamond-therapeutics-completes-phase-i-clinical-study-of-low-dose-psilocybin-in-healthy-human-subjects-301697266.html
https://endpts.com/push-to-reclassify-psilocybin-and-mdma-gains-bipartisan-support/
https://www.newsobserver.com/news/local/crime/article268445747.html
https://www.europeanpharmaceuticalreview.com/news/176019/psilocybin-improves-depression-symptoms-study-shows/
https://www.globenewswire.com/news-release/2022/10/03/2527311/0/en/Tryp-Therapeutics-Announces-Publication-of-International-PCT-Patent-Application-for-the-Intravenous-Administration-of-Psilocin-and-Psilocybin.html
https://www.globenewswire.com/news-release/2022/09/26/2522554/0/en/Tryp-Therapeutics-Strengthens-Intellectual-Property-Portfolio-with-Provisional-Patent-Applications-for-Fibromyalgia-Treatment-and-for-Crystalline-Forms-of-TRP-8803.html
https://www.globenewswire.com/news-release/2022/09/22/2521256/0/en/Origin-Therapeutics-Portfolio-Company-Xpira-Pharmaceuticals-Receives-FDA-Approval-For-Psilocybin-Trial-IND-Application.html
https://www.globenewswire.com/news-release/2022/09/22/2521053/0/en/Optimi-Health-ATMA-Journey-Centers-To-Proceed-With-Phase-I-Natural-Psilocybin-and-MDMA-Clinical-Trial-Application-to-Health-Canada.html
https://www.clinicaltrialsarena.com/news/mhra-psyence-adjustment-disorder-trial/
https://www.globenewswire.com/news-release/2022/09/16/2517486/0/en/Revive-Therapeutics-Provides-Update-on-the-Psilocybin-Clinical-Study-for-Methamphetamine-Use-Disorder-and-Oral-Psilocybin-Thin-Film-Strip-Program.html
https://www.globenewswire.com/news-release/2022/09/08/2512574/0/en/Optimi-Health-Completes-Largest-Legal-Natural-Psilocybin-Harvest-in-Canadian-History.html
https://www.newswire.ca/news-releases/filament-health-and-atma-journey-centers-announce-14-subjects-dosed-in-health-canada-approved-psilocybin-clinical-trial-881442362.html
https://www.prnewswire.com/news-releases/bmore-receives-fda-investigational-new-drug-approval-for-psilocybin-alcohol-use-disorder-program-phase-2b-clinical-trial-301609924.html
https://www.globenewswire.com/news-release/2022/08/10/2495816/0/en/Optimi-Health-Unveils-Canada-s-First-Natural-Therapeutic-Psilocybin-Product-For-Approved-Patients.html
https://www.globenewswire.com/news-release/2022/07/28/2487525/0/en/COMPASS-Pathways-launches-phase-II-clinical-trial-of-psilocybin-therapy-in-anorexia-nervosa.html
https://www.prnewswire.com/news-releases/bmore-submits-fda-investigational-new-drug-application-for-psilocybin-alcohol-use-disorder-program-301591794.html
https://endpts.com/unlikely-duo-leads-bipartisan-senate-bill-to-expand-right-to-try-into-mdma-and-psilocybin/
https://www.globenewswire.com/news-release/2022/07/13/2479065/0/en/Optimi-Health-Finalizes-Psilocybin-Supply-Agreement-With-Bloom-Psychedelic-Therapy-And-Research-Centre.html
https://www.globenewswire.com/news-release/2022/06/28/2470448/0/en/Optimi-Health-Initiates-Agreement-With-SABI-Mind-For-Therapeutic-Supplies-Of-Psilocybin-MDMA.html
https://www.prnewswire.com/news-releases/ceruvia-lifesciences-receives-fda-investigational-new-drug-approval-for-psilocybin-obsessive-compulsive-disorder-program-phase-2-trial-301572303.html
Market Place
Share 
